Routine Use of Antiretroviral Therapy to Prevent Mother-to-Child HIV Transmission in the Kafue District of Zambia
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00753324 |
Recruitment Status
:
Completed
First Posted
: September 16, 2008
Last Update Posted
: March 29, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The investigators will enroll a cohort of HIV-infected pregnant women accessing PMTCT services, to better understand the incremental benefits (e.g. reduction in HIV transmission, improvements in HIV-free survival) and risks (e.g. drug toxicities) of the routine HAART strategy, in comparison to HIV-infected pregnant women accessing the Zambian Standard of Care services.
The investigators will test the hypothesis that routine use of HAART produces significant reductions in HIV transmission rates, with only minimal side effects.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV Infections | Drug: Routine three-drug antiretroviral prophylaxis | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 284 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Routine Use of Antiretroviral Therapy to Prevent Mother-to-Child HIV Transmission in the Kafue District of Zambia (Impact of HAART to Prevent Pediatric AIDS in Rural Zambia). |
Study Start Date : | May 2009 |
Actual Primary Completion Date : | January 2012 |
Actual Study Completion Date : | January 2012 |

Arm | Intervention/treatment |
---|---|
Experimental: Routine three-drug antiretroviral prophyalxis
Cohort of 160 HIV-infected women, approached at > 28 weeks gestation and initiated on routine HAART for the purposes of PMTCT.
|
Drug: Routine three-drug antiretroviral prophylaxis
Women who are identified as HIV-infected will be offered routine combination antiretroviral prophylaxis starting at 28 weeks gestation (timing consistent with Zambian national guidelines for short-course ZDV). The first-line combination provided to pregnant women will be standardized following consultation with the Ministry of Health, but will likely include ZDV, lamivudine (3TC) and either NVP or lopinavir / ritonavir. In women who with moderate to severe anemia, ZDV is substituted with stavudine (d4T). In accordance with the Zambian national guidelines, any patients who are started on NVP will begin with a once daily dose for two weeks before increasing to the regular twice daily schedule
|
No Intervention: Control arm
A cohort of 160 women will be enrolled from the control clinics, from 28 weeks gestation onward. At these sites, the antenatal zidovudine will be offered, with provision of single-dose nevirapine for self-administration in labor. This practice is in accordance with the current standard of care recommended by the Zambian National Guidelines for PMTCT.
|
- HIV Infection [ Time Frame: 12 months ]
- HIV Infection [ Time Frame: 6 weeks, 6 months and 24 months ]
- Infant survival [ Time Frame: 12 and 24 months ]
- HIV-free survival [ Time Frame: 12 months and 24 months ]
- Incidence of maternal toxicity to HAART regimens [ Time Frame: 24 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Senior |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- HIV infected
- Pregnant women
- Ability to provide informed consent.
- Meets eligibility criteria for HAART initiation
Exclusion Criteria:
- Unwillingness to provide informed consent
- Below the age of legal consent

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00753324
Zambia | |
CIDRZ | |
Lusaka, Zambia, 34681 |
Principal Investigator: | Benjamin Chi, M.D | Centre for Infectious Disease Research in Zambia |
Publications of Results:
Responsible Party: | Benjamin Chi, MD, MSc, Associate Professor, University of North Carolina, Chapel Hill |
ClinicalTrials.gov Identifier: | NCT00753324 History of Changes |
Other Study ID Numbers: |
CIDRZ 1222/F070821006 |
First Posted: | September 16, 2008 Key Record Dates |
Last Update Posted: | March 29, 2016 |
Last Verified: | March 2016 |
Keywords provided by Benjamin Chi, MD, MSc, University of North Carolina, Chapel Hill:
PMTCT HAART Pregnancy |
HIV Infection HIV Transmission HIV Seronegativity |
Additional relevant MeSH terms:
HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases |
Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases |